Total Wealth Planning & Management Inc. Takes $496,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Total Wealth Planning & Management Inc. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,374 shares of the biopharmaceutical company's stock, valued at approximately $496,000.

Several other institutional investors have also recently modified their holdings of GILD. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $104,402,000. Talaria Asset Management Pty Ltd acquired a new stake in Gilead Sciences in the 4th quarter valued at $13,643,000. ABLE Financial Group LLC purchased a new position in Gilead Sciences in the 4th quarter worth approximately $234,000. LM Advisors LLC purchased a new stake in Gilead Sciences during the 4th quarter worth $1,110,000. Finally, Leigh Baldwin & CO. LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $430,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $0.65 during mid-day trading on Wednesday, hitting $108.44. The company's stock had a trading volume of 4,591,543 shares, compared to its average volume of 7,722,873. The stock's fifty day moving average price is $105.36 and its two-hundred day moving average price is $100.57. The stock has a market capitalization of $134.89 billion, a P/E ratio of 293.08, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the business posted ($1.32) EPS. The company's revenue was down .3% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.91%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. BMO Capital Markets lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Finally, DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,929 shares of company stock worth $5,644,780 in the last 90 days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.